Keep pulling the thread on Eric Topol.
B-cell depletion therapies have achieved unprecedented cures for autoimmune diseases such as Lupus, progressive systemic sclerosis, multiple sclerosis, and dermatomyositis.
Personalized cancer vaccines that use proteins from a patient's own tumor are showing the ability to cure pancreatic and kidney cancers in ongoing clinical trials.
Using the P-tau-217 blood biomarker and AI models, it is possible to predict the onset of mild cognitive impairment from Alzheimer's disease up to 18 years before symptoms appear.
The GLP-1 drug class, which includes Ozempic and Zepbound, is considered the most momentous drug class in medical history.
GLP-1 drugs are currently in large clinical trials to test their effectiveness in preventing Alzheimer's disease in people who are not overweight.
Levels of the Alzheimer's risk biomarker p-tau-217 can be reduced by 50% to 80% through exercise and other lifestyle interventions.
The FDA approved recent Alzheimer's drugs primarily because they cleared amyloid from brain scans, despite having significant risks and limited clinical efficacy.
Current age-based mass cancer screening programs in the United States cost over $100 billion annually but only detect 14% of cancers.
The WELDERLY study found few significant genetic explanations for longevity in its cohort of individuals who lived to an average age of 87 without any major age-related diseases.
Companies like Altos are heavily invested in age-reversal technologies such as cellular reprogramming and senolytics, which have shown results in rodents but not yet in humans.
Novo Nordisk scientist Lotte Knudsen was a key internal advocate for testing GLP-1 drugs for obesity, despite the company's initial reluctance.
The concept of "organ clocks" for measuring the biological age of specific organs was first developed by a research group at Stanford University led by Tony Wyss-Coray.